[Drug-induced neuroleptic malignant syndrome]

Nihon Rinsho. 2007 Oct 28:65 Suppl 8:331-5.

[Article in Japanese]

Authors

Chiaki Kawanishi¹, Taku Furuno, Ikuko Kishida

Affiliation

¹ Department of Psychiatry, Yokohama City University School of Medicine

PMID: 18074558

No abstract available

Publication types

Review

MeSH terms

Biomarkers / blood
Bromocriptine / therapeutic use
Creatine Kinase, MM Form / blood
Cytochrome P-450 CYP2D6 / genetics
Dantrolene / therapeutic use
Diagnosis, Differential
Dopamine Agonists / therapeutic use
Dopamine Antagonists / administration & dosage
Dopamine Antagonists / adverse effects
Humans
Neuroleptic Malignant Syndrome / diagnosis
Neuroleptic Malignant Syndrome / etiology*
Neuroleptic Malignant Syndrome / physiopathology
Neuroleptic Malignant Syndrome / therapy
Polymorphism, Genetic
Psychotropic Drugs / administration & dosage
Psychotropic Drugs / adverse effects*
Reference Standards
Risk Factors
Time Factors

Substances

Biomarkers
Dopamine Agonists
Dopamine Antagonists
Psychotropic Drugs
Bromocriptine
Cytochrome P-450 CYP2D6
Creatine Kinase, MM Form
Dantrolene